OncoCyte (OCX) Competitors $3.00 -0.03 (-0.99%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OCX vs. ACHL, DRRX, DBVT, ICCC, AWH, CYBN, CRBU, MDWD, GOSS, and FULCShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Achilles Therapeutics (ACHL), DURECT (DRRX), DBV Technologies (DBVT), ImmuCell (ICCC), Aspira Women's Health (AWH), Cybin (CYBN), Caribou Biosciences (CRBU), MediWound (MDWD), Gossamer Bio (GOSS), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Achilles Therapeutics DURECT DBV Technologies ImmuCell Aspira Women's Health Cybin Caribou Biosciences MediWound Gossamer Bio Fulcrum Therapeutics OncoCyte (NASDAQ:OCX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor OCX or ACHL? Achilles Therapeutics received 9 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 8.42% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes88.42%Underperform Votes8791.58% Achilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Does the media prefer OCX or ACHL? In the previous week, OncoCyte had 1 more articles in the media than Achilles Therapeutics. MarketBeat recorded 2 mentions for OncoCyte and 1 mentions for Achilles Therapeutics. Achilles Therapeutics' average media sentiment score of 0.98 beat OncoCyte's score of 0.30 indicating that Achilles Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OncoCyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achilles Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, OCX or ACHL? OncoCyte has higher revenue and earnings than Achilles Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$1.50M33.66-$27.78MN/AN/AAchilles TherapeuticsN/AN/A-$69.67M-$1.59-0.64 Which has more volatility & risk, OCX or ACHL? OncoCyte has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Achilles Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Do analysts prefer OCX or ACHL? OncoCyte presently has a consensus target price of $4.06, suggesting a potential upside of 35.42%. Achilles Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 292.16%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is OCX or ACHL more profitable? Achilles Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -3,558.46%. Achilles Therapeutics' return on equity of -47.24% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-3,558.46% -149.88% -45.79% Achilles Therapeutics N/A -47.24%-41.69% Do insiders & institutionals have more ownership in OCX or ACHL? 55.4% of OncoCyte shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 1.6% of OncoCyte shares are held by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAchilles Therapeutics beats OncoCyte on 10 of the 15 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.49M$2.31B$5.50B$8.53BDividend YieldN/A0.69%5.13%4.14%P/E RatioN/A4.22116.1015.23Price / Sales33.6641.041,496.2597.74Price / CashN/A16.3639.7434.10Price / Book1.213.164.775.07Net Income-$27.78M$29.98M$119.06M$225.46M7 Day Performance-1.32%-3.56%0.80%0.37%1 Month Performance-1.64%-0.60%5.65%3.57%1 Year Performance27.66%-2.99%36.75%29.43% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.1855 of 5 stars$3.00-1.0%$4.06+35.4%+29.3%$50.49M$1.50M0.00120Analyst ForecastACHLAchilles Therapeutics2.8564 of 5 stars$1.02+2.0%$4.00+292.2%+21.4%$41.91MN/A-0.64250Positive NewsDRRXDURECT2.7838 of 5 stars$1.34+1.5%$21.00+1,467.2%-55.0%$41.59M$8.55M-2.2080Positive NewsDBVTDBV Technologies3.2525 of 5 stars$0.76-2.6%$6.00+694.1%-63.0%$72.92M$15.73M-0.82106Upcoming EarningsAnalyst ForecastICCCImmuCell0.6704 of 5 stars$3.58-0.8%N/A-29.9%$28.04M$23.22M-6.7575Positive NewsAWHAspira Women's Health1.2045 of 5 stars$0.90flat$4.40+388.9%-80.8%$14.46M$9.15M-0.62110Analyst ForecastGap UpCYBNCybin1.8174 of 5 stars$9.99-0.4%$50.50+405.5%N/A$199.72MN/A-1.6450CRBUCaribou Biosciences2.1193 of 5 stars$2.21+12.8%$11.25+409.0%-38.3%$199.70M$34.48M-1.59100Upcoming EarningsMDWDMediWound1.4641 of 5 stars$18.37+1.5%$29.00+57.9%+142.3%$198.21M$18.69M-8.5080GOSSGossamer Bio4.4818 of 5 stars$0.87flat$9.20+953.0%+82.0%$197.66MN/A-2.24180Short Interest ↓Positive NewsFULCFulcrum Therapeutics3.4943 of 5 stars$3.21+1.6%$9.33+190.8%-14.4%$197.19M$81.63M-9.17100Upcoming EarningsShort Interest ↓Positive News Related Companies and Tools Related Companies Achilles Therapeutics Alternatives DURECT Alternatives DBV Technologies Alternatives ImmuCell Alternatives Aspira Women's Health Alternatives Cybin Alternatives Caribou Biosciences Alternatives MediWound Alternatives Gossamer Bio Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
